tbuckley/cabot-search huggingface dataset:
EPID-27GLIOSTRY (GLIOBLASTOMA REGISTRY) OF THE AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY): ANALYSIS OF FACTORS INFLUENCING SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING THE NITROSOUREA FOTEMUSTINE AT FIRST PROGRESSION FOLLOWING THE STUPP REGIMEN
Authors: Riccardo Soffietti, Giuseppe Lombardi, Silvia Scoccianti, Maria Grazia Fabrini, Antonio Silvani, Mario Santoni, Andrea Pace, Antonio Marinelli, Ivan Lolli, Mario Balducci, Mauro Arcicasa, Maurizio Salvati, Andrea Sponghini, Simona Vallarelli, Manuela Caroli, Francesca Imbesi, Donato Bilancia, Marina Faedi, Roberta Rudà
Journal: Neuro-Oncology (2015)
Exposure to ultrafine particles and respiratory hospitalisations in five European cities
Authors: Evangelia Samoli, Zorana Jovanovic Andersen, Klea Katsouyanni, Frauke Hennig, Thomas A.J. Kuhlbusch, Tom Bellander, Giorgio Cattani, Josef Cyrys, Francesco Forastiere, Bénédicte Jacquemin, Markku Kulmala, Timo Lanki, Steffen Loft, Andreas Massling, Aurelio Tobias, Massimo Stafoggia
Journal: European Respiratory Journal (2016)

Epidemiological evidence on the associations between exposure to ultrafine particles (UFP), with aerodynamic electrical mobility diameters &lt;100 nm, and health is limited. We gathered data on UFP from five European cities within 2001–2011 to investigate associations between short-term changes in concentrations and respiratory hospitalisations. We applied city-specific Poisson regression models and combined city-specific estimates to obtain pooled estimates. We evaluated the sensitivity of our findings to co-pollutant adjustment and investigated effect modification patterns by period of the year, age at admission and specific diagnoses. Our results for the whole time period do not support an association between UFP and respiratory hospitalisations, although we found suggestive associations among those 0–14 years old. We nevertheless report consistent adverse effect estimates during the warm period of the year, statistically significant after lag 2 when an increase by 10 000 particles per cm 3 was associated with a 4.27% (95% CI 1.68–6.92%) increase in hospitalisations. These effect estimates were robust to particles' mass or gaseous pollutants adjustment. Considering that our findings during the warm period may reflect better exposure assessment and that the main source of non-soluble UFP in urban areas is traffic, our results call for improved regulation of traffic emissions.
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
Authors: K K Starheim, T Holien, K Misund, I Johansson, K A Baranowska, A-M Sponaas, H Hella, G Buene, A Waage, A Sundan, G Bjørkøy
Journal: Blood Cancer Journal (2016)

Abstract Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, but inherent and acquired resistance to the drug remains a problem. We here show that bortezomib-induced cytotoxicity was completely dampened when cells were supplemented with cysteine or its derivative, glutathione (GSH) in ANBL-6 and INA-6 myeloma cell lines. GSH is a major component of the antioxidative defense in eukaryotic cells. Increasing intracellular GSH levels fully abolished bortezomib-induced cytotoxicity and transcriptional changes. Elevated intracellular GSH levels blocked bortezomib-induced nuclear factor erythroid 2-related factor 2 (NFE2L2, NRF2)-associated stress responses, including upregulation of the xCT subunit of the Xc- cystine-glutamate antiporter. INA-6 cells conditioned to increasing bortezomib doses displayed reduced bortezomib sensitivity and elevated xCT levels. Inhibiting Xc- activity potentiated bortezomib-induced cytotoxicity in myeloma cell lines and primary cells, and re-established sensitivity to bortezomib in bortezomib-conditioned cells. We propose that intracellular GSH level is the main determinant of bortezomib-induced cytotoxicity in a subset of myeloma cells, and that combined targeting of the proteasome and the Xc- cystine-glutamate antiporter can circumvent bortezomib resistance.
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Authors: Karine Dahan, Hanna Debiec, Emmanuelle Plaisier, Marine Cachanado, Alexandra Rousseau, Laura Wakselman, Pierre-Antoine Michel, Fabrice Mihout, Bertrand Dussol, Marie Matignon, Christiane Mousson, Tabassome Simon, Pierre Ronco
Journal: Journal of the American Society of Nephrology (2016)

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12.5-24.0) months and 17.0 (interquartile range, 13.0-23.0) months in NIAT-rituximab and NIAT groups, respectively. Primary outcome was a combined end point of complete or partial remission of proteinuria at 6 months. At month 6, 13 (35.1%; 95% confidence interval [95% CI], 19.7 to 50.5) patients in the NIAT-rituximab group and eight (21.1%; 95% CI, 8.1 to 34.0) patients in the NIAT group achieved remission (P=0.21). Rates of antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) depletion in NIAT-rituximab and NIAT groups were 14 of 25 (56%) and one of 23 (4.3%) patients at month 3 (P<0.001) and 13 of 26 (50%) and three of 25 (12%) patients at month 6 (P=0.004), respectively. Eight serious adverse events occurred in each group. During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months. These data suggest that PLA2R-Ab levels are early markers of rituximab effect and that addition of rituximab to NIAT does not affect safety.
Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy
Authors: Farhad Ravandi, Jean-Pierre Issa, Guillermo Garcia-Manero, Susan O’Brien, Sherry Pierce, Jenny Shan, Srdan Verstovsek, Stefan Faderl, Jorge Cortes, Hagop Kantarjian
Journal: Blood (2008)
Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function
Authors: Hyo Youl Moon, Andreas Becke, David Berron, Benjamin Becker, Nirnath Sah, Galit Benoni, Emma Janke, Susan T. Lubejko, Nigel H. Greig, Julie A. Mattison, Emrah Duzel, Henriette van Praag
Journal: Cell Metabolism (2016)
Case 19-1970
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Donald W. Seldin, Benjamin Castleman
Journal: New England Journal of Medicine (1970)

Presentation of Case First admission. A twenty-nine-year-old woman was admitted to the hospital because of pain in both costovertebral angles.One year previously she experienced flank pain, fever, chills, urgency of urination and nocturia and was treated with penicillin. A similar episode occurred six months later. Five days before entry pain and urgency of urination recurred in association with the passage of cloudy, foul-smelling urine.Gastrointestinal hemorrhage had occurred seven years, five years and one year before entry. Seven years before admission an upper gastrointestinal series demonstrated a duodenal ulcer and bilateral nephrocalcinosis. There was no history of renal . . .
Increase of cases of legionellosis in Latvia, 2011
Authors: B Rozentale, A Bormane, J Perevoščikovs, I Lucenko, A Brila
Journal: Eurosurveillance (2011)

An increased number of legionellosis cases in 2011 has been reported in Latvia, compared to the ten previous years. A total of 30 legionellosis cases (1.35 per 100,000 inhabitants), including 19 females, have been confirmed until the end of September 2011. The majority of cases (n=23) were inhabitants of the capital city Riga. The reason for the increase in legionellosis is unclear. Twenty-six of the 30 cases are not travel-related.
Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis
Authors: Simona Salati, Roberta Zini, Simona Nuzzo, Paola Guglielmelli, Valentina Pennucci, Zelia Prudente, Samantha Ruberti, Sebastiano Rontauroli, Ruggiero Norfo, Elisa Bianchi, Costanza Bogani, Giada Rotunno, Tiziana Fanelli, Carmela Mannarelli, Vittorio Rosti, Silvia Salmoiraghi, Daniela Pietra, Sergio Ferrari, Giovanni Barosi, Alessandro Rambaldi, Mario Cazzola, Silvio Bicciato, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini
Journal: Blood (2015)
A phase I trial assessing the maximum tolerated dose (MTD) and pharmacokinetics of intrapleural bevacizumab after pleural puncture in breast cancer patients with symptomatic recurrent metastatic pleural effusion: The BEVAP trial.
Authors: Benoit Rousseau, Anne Hulin, Xavier Paoletti, Florence Coussy, Fawzia Mefti, Coraline Dubot, Alexia Savignoni, Christian Jayr, Isabelle Turbiez, Pierre Mordant, Etienne Brain, Maya Gutierrez
Journal: Journal of Clinical Oncology (2015)

TPS632 Background: Metastatic pleural effusion (MPE) is frequently observed in advanced cancer, especially in breast carcinoma. Invalidating symptoms may be associated with these effusions as shortness of breath, pain or asthenia, decreased quality of life and survival. Despite effective systemic treatment, many patient still experiment local discomfort and respiratory symptoms. Local management remains the cornerstone, not edged out by the development of new systemic agents. Surgical talc pleurodesis is indeed the main validated local management to prevent recurrence in patients with good performance status, but it is often not possible. Other techniques, as intrapleural (IP) catheter to facilitate puncture, are attractive in order to relieve symptoms, improve quality of life of patients and deliver IP agents. VEGF is a proangiogenic factor increasing endothelial permeability implicated in MPE. Bevacizumab is an anti-VEGF monoclonal antibody. Encouraging results were observed with high dose IV bevacizuma...
PD1-2-6: Transoesophageal endoscopic ultrasound with fine needle aspiration(EUS-FNA) in lung cancer staging: does lymph node size matter?
Authors: Kurt G. Tournoy, Frank Vermassen, Lieve Vanwalleghem, Frederic De Rijck, Marleen Praet, Georges Van Maele, Jan Van Meerbeeck
Journal: Journal of Thoracic Oncology (2007)
Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia
Authors: Justine Frija-Masson, Laurence Bassinet, Isabelle Honoré, Nadine Dufeu, Bruno Housset, André Coste, Jean Francois Papon, Estelle Escudier, Pierre-Régis Burgel, Bernard Maître
Journal: Thorax (2016)

<h3>Introduction</h3> Primary ciliary dyskinesia (PCD) is a genetic disease characterised by abnormalities in ciliary function, responsible for chronic pulmonary and sinonasal diseases. Adult clinical features and outcome are poorly described. <h3>Objectives</h3> To assess the clinical characteristics and disease progression in adults with PCD. <h3>Methods</h3> Bicentric retrospective study, focusing on adults (≥18 years) with an asserted diagnosis of PCD based on the presence of bronchiectasis with typical ultrastructural defect of cilia and/or situs inversus (SI). Clinical symptoms, respiratory function, extent of bronchiectasis, microbiology and molecular analysis were assessed. Results are expressed as median (25th; 75th centile). <h3>Results</h3> 78 patients were included with a median follow-up of 8.1 years. 91% of patients had respiratory symptoms and 95% had chronic rhinosinusitis. Half of ultrastructural defects concerned dynein arms. Respiratory function was significantly lower in women (FEV<sub>1</sub>=60% predicted (50; 76), vs 77% (62; 95), p=0.009) and in patients with chronic airway <i>Pseudomonas aeruginosa</i> (PA, n=21) infection (FEV<sub>1</sub>=60% (48; 71) vs 75% (55; 89), p=0.04). FEV<sub>1</sub> was associated with gender (regression coefficient for men =13.8, p=0.009), chest CT score (r=−0.42, p&lt;0.001) but not with age at diagnosis, SI or body mass index. FEV<sub>1</sub> decline was −13.4 mL/year (−42.8; +11.9) and was greater in women (−29.3 mL/year, (−59.7; −11.9), vs –2.0 mL/year (−26.9; +25.4), p=0.002). Three patients had severe respiratory failure. <h3>Conclusions</h3> Alteration of respiratory function in adults with PCD is heterogeneous and usually moderate but appears more severe in women and in patients with chronic PA infection. Only 4% of patients develop chronic respiratory failure.
Crucial Role of Regulatory T Cells in Predicting the Outcome of the T Cell Engaging Antibody Blinatumomab in Relapsed and Refractory B Precursor ALL Patients
Authors: Johannes Duell, Marcus Dittrich, Tanja Bedke, Tobias Mueller, Leo Rasche, Thomas Dandekar, Hermann Einsele, Max S. Topp
Journal: Blood (2014)
Case 20-2016
Authors: Dean Eliott, George N. Papaliodis, Marlene L. Durand, Sarah E. Turbett
Journal: New England Journal of Medicine (2016)

A 50-year-old man with psoriatic arthritis and HIV infection presented with cloudy vision, decreased hearing, and gait instability. Two months earlier, the patient had begun taking antiretroviral medications. A diagnostic test result was received.
Addition of ATRA to the Maintenance Protocol Did Not Improve Disease-Free Survival: Results of the Russian APL Trial.
Authors: Elena N. Parovichnikova, Valeri G. Savchenko, Valentin G. Isaev, Elena N. Shuravina, Irina A. Demidova, Julia V. Olshanskaya, Andrey V. Misiurin, Sergey M. Kulikov
Journal: Blood (2007)
Instrument for Predicting Early Stroke Recurrence: Ambiguity and Biases
Authors: Shah Mohammed Faisal, Amith S. Kumar, Aastha Takkar
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis
Authors: Sebastien Viatte, Jonathan Massey, John Bowes, Kate Duffus, Stephen Eyre, Anne Barton, Jane Worthington
Journal: Arthritis & Rheumatology (2016)

Objective Genetic polymorphisms within the HLA region explain only a modest proportion of anti–cyclic citrullinated peptide (anti‐CCP)–negative rheumatoid arthritis (RA) heritability. However, few non‐HLA markers have been identified so far. This study was undertaken to replicate the associations of anti‐CCP–negative RA with non‐HLA genetic polymorphisms demonstrated in a previous study. Methods The Rheumatoid Arthritis Consortium International densely genotyped 186 autoimmune‐related regions in 3,339 anti‐CCP–negative RA patients and 15,870 controls across 6 different populations using the Illumina ImmunoChip array. We performed a case–control replication study of the anti‐CCP–negative markers with the strongest associations in that discovery study, in an independent cohort of anti‐CCP–negative UK RA patients. Individuals from the arcOGEN Consortium and Wellcome Trust Case Control Consortium were used as controls. Genotyping in cases was performed using Sequenom MassArray technology. Genome‐wide data from controls were imputed using the 1000 Genomes Phase I integrated variant call set release version 3 as a reference panel. Results After genotyping and imputation quality control procedures, data were available for 15 non‐HLA single‐nucleotide polymorphisms in 1,024 cases and 6,348 controls. We confirmed the known markers ANKRD55 (meta‐analysis odds ratio [OR] 0.80; P = 2.8 × 10 −13 ) and BLK (OR 1.13; P = 7.0 × 10 −6 ) and identified new and specific markers of anti‐CCP–negative RA (prolactin [ PRL ] [OR 1.13; P = 2.1 × 10 −6 ] and NFIA [OR 0.85; P = 2.5 × 10 −6 ]). Neither of these loci is associated with other common, complex autoimmune diseases. Conclusion Anti‐CCP–negative RA and anti‐CCP–positive RA are genetically different disease subsets that only partially share susceptibility factors. Genetic polymorphisms located near the PRL and NFIA genes represent examples of genetic susceptibility factors specific for anti‐CCP–negative RA.
Factors influencing advanced cancer patients’ preferences for quality or length of life.
Authors: Eva C. Winkler, Halina Sklenarova, Mechthild Hartmann, Pia Heussner, Matthias Villalobos, Dirk Jaeger, Katsiaryna Laryionava
Journal: Journal of Clinical Oncology (2014)

9576 Background: The integration of individual patients' preferences is paramount for patient-oriented care in oncology at the End of Life (EOL). The aim of this study was to explore patients' preferences for Quality (QL) or Length of Life (LL) and the factors influencing them. In addition, communication preferences of patients about limiting treatment were explored. Methods: We surveyed 194 cancer patients at the National Center for Tumour diseases and the Thorax Clinic at Heidelberg University using a set of questionnaires. Socio-demographic, clinical data, preferences regarding QL and LL, communication preferences cancer-related distress and family role in the decision-making were assessed. Results: Patients' attitudes toward treatment could be categorized into striving for QL, striving for LL, and no clear preference. Patients' preferences were slightly higher for QL (mean=3.5; SD=0.7) than for LL (mean=3.15; SD=0.9). Patients who indicated that their next of kin play an important role in therapeutic decisions were more likely to strive for LL (p=.01). Patients who preferred LL tended to avoid communications with their physicians about limiting treatment (p=.03) whereas patients who strived for QL preferred their physicians initiating this discussion early on (p=.00). Patients were predominantly men (68%); mean age was 63 years (SD=10.3). Age, gender, prognosis and cancer-related distress had no impact on preferences for QL or LL. Conclusions: Family involvement in treatment decisions had considerable impact on patients' preferences and was associated with patients striving for LL. Those patients did not want their oncologists to discuss treatment limitation with them. Hence, in orchestrating decision making about cancer specific treatment near the EOL it is important for oncologists to involve the family and enable the communication about realistic treatment goals early on.
Outcomes of Second Autologous Peripheral Blood Stem Cell Transplant in Multiple Myeloma Patients with Renal Dysfunction
Authors: Lakshminarayanan Nandagopal, J. Christine Ye, Richard Manasa, Muneer H. Abidi, Lois Ayash, Lawrence G Lum, Joseph P. Uberti, Voravit Ratanatharathorn, Jeffrey Zonder, Divaya Bhutani, Abhinav Deol
Journal: Blood (2014)
The Management of Sexually Transmitted Diseases.
Authors: D R Howard
Journal: Annals of Internal Medicine (1980)

Patients with sexually transmitted diseases (STDs) in developing countries are often untreated for long periods of time or receive ineffective treatment, producing complications that can lead to infertility, blindness, and even death. In addition, there is growing research evidence that people with bacterial or viral STDs are more likely to acquire--and perhaps transmit--the human immunodeficiency virus (HIV). STD control programs in developing countries must be reorganized to include: 1) good management of patients with STDs and their contacts, 2) case finding for syphilis in the antenatal population, 3) screenings and case findings for gonorrhea in high-risk groups, and 4) systematic prophylaxis for ophthalmia neonatorum in newborns. Since diagnosis before treatment is problematic in rural areas, the World Health Organization recommends simple treatment protocols based on the most common STD symptoms--urethral discharge; gynecological complaints such as vaginal discharge, low abdominal pain, or dysuria; genital ulceration; and inguinal bubo, a swelling of the lymph nodes in the groin. Other components of this approach include standardized treatment, contact tracing and treatment, health education targeted at high-risk groups, follow-up and case referral where necessary, and the collection of simple statistics on treatment efficacy and STD epidemiology. The incidence of STDs in developing countries is steadily increasing as a result of urbanization, increased numbers of young people, and delayed age at marriage. However, this situation can be combatted through application of treatment protocols, technological advances, improvements in the health care delivery system, and awareness on the part of policy makers of the seriousness of the STD problem.
Outcomes After Anticoagulation for Traumatic Arterial Injuries of the Extremity
Authors: Misty Humphries, Mandy K. Blume, Maria Ceja Rodriguez, Joseph J. DuBose, Joseph M. Galante
Journal: JAMA Surgery (2016)

This cohort study examines associations between anticoagulation during arterial repair or bypass and repair thrombosis or limb amputation among patients with traumatic vascular injury of the extremities.
Measuring and Improving Quality
Authors: David W. Baker, Mark R. Chassin
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sporadic infection caused by enterohemorrhagic d’Escherichia coli O157
Authors: F Allerberger, L Beutin, T Cheasty, G Gonedera, H Karch
Journal: Eurosurveillance (1999)

In 1997 the Austrian Federal Ministry of Health established a reference laboratory for enterohaemorrhagic Escherichia coli at the federal public health laboratory in Innsbruck. The reference laboratory investigates sources of infection causing food poison